PriceTargets.com logo

BioSpecifics Technologies - BSTC Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$88.53 As of 12/2/2020 01:00 AM ET
+0 (0.00%)
Get New BioSpecifics Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BSTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BSTC

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for BioSpecifics Technologies in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $88.53.

This chart shows the closing price for BSTC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in BioSpecifics Technologies. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/20/2020HC WainwrightDowngradeBuy ➝ Neutral$100.00 ➝ $88.50Low
7/7/2020HC WainwrightBoost TargetBuy$90.00 ➝ $100.00High
6/16/2020HC WainwrightReiterated RatingBuy$90.00High
11/20/2019HC WainwrightReiterated RatingBuy$90.00Low
10/11/2019HC WainwrightSet TargetBuy$90.00Medium
8/12/2019HC WainwrightReiterated RatingBuy$85.00 ➝ $90.00High
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
BioSpecifics Technologies logo
BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.
Read More

Today's Range

Now: $88.53
Low: $88.53
High: $88.53

50 Day Range

MA: $88.47
Low: $88.22
High: $88.53

52 Week Range

Now: $88.53
Low: $42.00
High: $89.15

Volume

N/A

Average Volume

61,105 shs

Market Capitalization

$650.25 million

P/E Ratio

37.51

Dividend Yield

N/A

Beta

0.24

Frequently Asked Questions

What sell-side analysts currently cover shares of BioSpecifics Technologies?

The following Wall Street research analysts have issued stock ratings on BioSpecifics Technologies in the last twelve months:
View the latest analyst ratings for BSTC.

What is the current price target for BioSpecifics Technologies?

0 Wall Street analysts have set twelve-month price targets for BioSpecifics Technologies in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for BioSpecifics Technologies in the next year.
View the latest price targets for BSTC.

What is the current consensus analyst rating for BioSpecifics Technologies?

BioSpecifics Technologies currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BSTC.

What other companies compete with BioSpecifics Technologies?

Other companies that are similar to BioSpecifics Technologies include Stemline Therapeutics, Akouos, OPKO Health, Lexicon Pharmaceuticals and Albireo Pharma. Learn More about companies similar to BioSpecifics Technologies.

How do I contact BioSpecifics Technologies' investor relations team?

BioSpecifics Technologies' physical mailing address is 2 Righter Parkway Suite 200, Wilmington DE, 19803. The biopharmaceutical company's listed phone number is 302-842-8450 and its investor relations email address is [email protected]. The official website for BioSpecifics Technologies is www.biospecifics.com. Learn More about contacing BioSpecifics Technologies investor relations.